Celgene (CELG) -10.2% after EU regulators request more data about widening authorization of the firm's multiple myeloma treatment Revlimid to treat newly diagnosed patients and as a maintenance therapy. Celgene is pulling the submission and will resubmit it with more data, and the firm is "re-evaluating" a similar FDA application. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 6:33PM)
at Investor's Business Daily (Fri, 6:51PM)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Feb 26, 2015)
at Nasdaq.com (Feb 24, 2015)
at Zacks.com (Feb 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs